A federal panel of experts on Wednesday recommended an expansion of RSV vaccinations for adults and a new combination shot as ...

A study by former Junior Associate Professor Kazuo Takayama, currently a professor of the Institute of Science Tokyo, ...

A federal panel of experts on Wednesday recommended an expansion of RSV vaccinations for adults and a new combination shot as ...

The South Dakota parents of seven children were "grateful," but admittedly "busy," during a special reunion with NICU staff ...

The highest risk of transmission of SARS-CoV-2 was in the first 72 hours at room temperature and first 24 hours at 37℃.

Pfizer's Abrysvo and GSK's Arexvy both received FDA-approval b in 2024 to include immunization of adults aged 50 to 59 years at increased risk for RSV disease.

The committee endorsed lowering the age at which some people can receive RSV vaccines, but stopped short of recommending ...

A year after narrowing its recommendation for who should use vaccines to defend against respiratory syncytial virus (RSV), a ...

Pfizer Inc. (NYSE: PFE) announced today that the U.S. Centers for Disease Control and Prevention’s (CDC) Advisory Committee ...

The CDC's Advisory Committee on Immunization Practices is meeting to review vaccine guidelines, including COVID-19 and ...